147 related articles for article (PubMed ID: 34319022)
21. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
22. Predictive Value of BRAF
Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
[TBL] [Abstract][Full Text] [Related]
23. Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma.
Condello V; Macerola E; Ugolini C; De Napoli L; Romei C; Materazzi G; Elisei R; Basolo F
Head Neck; 2018 Aug; 40(8):1752-1758. PubMed ID: 29566452
[TBL] [Abstract][Full Text] [Related]
24. BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia.
Zhou D; Li Z; Bai X
Med Sci Monit; 2018 Sep; 24():6795-6808. PubMed ID: 30254191
[TBL] [Abstract][Full Text] [Related]
25. Conventional Ultrasound, Immunohistochemical Factors and BRAF
Chen J; Li XL; Zhao CK; Wang D; Wang Q; Li MX; Wei Q; Ji G; Xu HX
Ultrasound Med Biol; 2018 Nov; 44(11):2296-2306. PubMed ID: 30100099
[TBL] [Abstract][Full Text] [Related]
26. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
[TBL] [Abstract][Full Text] [Related]
27. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion.
Chakraborty A; Narkar A; Mukhopadhyaya R; Kane S; D'Cruz A; Rajan MG
Endocr Pathol; 2012 Jun; 23(2):83-93. PubMed ID: 22105775
[TBL] [Abstract][Full Text] [Related]
28. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
29. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
30. BRAF(V600E) mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma.
Jing FJ; Liang J; Liang ZY; Meng C; Long W; Li XY; Lin YS
Chin Med J (Engl); 2013 Aug; 126(16):3013-8. PubMed ID: 23981603
[TBL] [Abstract][Full Text] [Related]
31. BRAF V600E and TERT promoter mutations in paediatric and young adult papillary thyroid cancer and clinicopathological correlation.
Chakraborty D; Shakya S; Ballal S; Agarwal S; Bal C
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1465-1474. PubMed ID: 33027050
[TBL] [Abstract][Full Text] [Related]
32. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
33. Heterogenous nature of gene expression patterns in BRAF-like papillary thyroid carcinomas with BRAF
Nagayama Y; Mishima H
Endocrine; 2019 Dec; 66(3):607-613. PubMed ID: 31478162
[TBL] [Abstract][Full Text] [Related]
34. Effect of BRAF V600E mutation detection of fine-needle aspiration biopsy on diagnosis and treatment guidance of papillary thyroid carcinoma.
Qi W; Shi C; Zhang P; Feng L; Wang J; Chen D
Pathol Res Pract; 2020 Aug; 216(8):153037. PubMed ID: 32703500
[TBL] [Abstract][Full Text] [Related]
35. Increase in Papillary Thyroid Cancer Incidence Is Accompanied by Changes in the Frequency of the BRAF V600E Mutation: A Single-Institution Study.
Kowalska A; Walczyk A; Kowalik A; Pałyga I; Trybek T; Kopczyński J; Kajor M; Chrapek M; Pięciak L; Chłopek M; Góźdź S; Kamiński G
Thyroid; 2016 Apr; 26(4):543-51. PubMed ID: 26889698
[TBL] [Abstract][Full Text] [Related]
36. Clinical Analysis of BRAF
Dong SY; Chen J; Xia EJ; Lin RX; Du HY; Wang OC; Zhang XH; Hao RT
Am Surg; 2020 May; 86(5):450-457. PubMed ID: 32684022
[TBL] [Abstract][Full Text] [Related]
37. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
38. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
40. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
